頁籤選單縮合
題名 | 大腸癌各分期的藥物治療=Pharmacotherapy of Colon Cancer in Each Stage |
---|---|
作者 | 陳弘益; | 書刊名 | 藥學雜誌 |
卷期 | 31:4=125 2015.12[民104.12] |
頁次 | 頁68-73 |
分類號 | 418.31 |
關鍵詞 | 大腸直腸癌; 藥物治療; Colorectal cancer; Pharmacotherapy; |
語文 | 中文(Chinese) |
中文摘要 | 大腸直腸癌病人,診斷時超過一半為第二期或第三期,即使切除原發性腫瘤, 第二期病人約有15-30%而第三期病人約有50-60%最後會遠端轉移或復發,導致預 後不佳。近年來治療大腸直腸癌有許多進展,合併使用5-fluororuracil 及 oxaliplatin 或 irinotecan 使得存活率增加,而標靶治療藥物,像是血管內皮細胞生長因子抑 制劑 bevacizumab (Avastin)、aflibercept (Zaltrap, 柔癌捕),及上皮生長因子受體抑 制劑-cetuximab (Erbitux)、panitumumab (Vectibix),多重標靶酪胺酸激酶抑制劑 regorafenib 的出現,提供病人更多的治療機會。有別於單一藥物藥理機轉介紹,本文 將簡介大腸癌各分期臨床治療所需的化療藥品組合。 |
英文摘要 | More than a half of patients have stage II (T34N0M0) or stage III (TxN1M0) colorectal cancer at the time of diagnosis. Approximately 15-30% of patients with stage II and 50-60% of patients with stage III disease will eventually develop distant metastases or locoregional recurrent disease, resulting in poor outcomes even when these patients have resectable primary tumors. In recent years, there is a lot of progress in the treatment of colorectal cancer. Combination therapy of 5-fluororuracil and oxaliplatin or irinotecan increased survival rate of colorectal cancer patient. Targeted therapy such as vascular endothelial growth factor (bevacizumab, aflibercept), epidermal growth factor receptor (cetuximab, panitumumab) and multi-kinase inhibitor (regorafenib) provides more opportunities for these patients. Unlike individual drug mechanism introduction, this article will introduce clinical chemotherapy which will be used in each stage of colon cancer. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。